FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
- Daraxonrasib, an oral RAS inhibitor, was approved for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent systemic therapy is not appropriate.
- The approval introduces a targeted oral treatment option for a malignancy in which RAS signaling drives the large majority of tumors.1Daraxonr
Unverified
- Daraxonrasib, an oral RAS inhibitor, was approved for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent systemic therapy is not appropriate.
- The approval introduces a targeted oral treatment option for a malignancy in which RAS signaling drives the large majority of tumors.1Daraxonr
Sources: Pharmacytimes